OncoCyte (NYSEAMERICAN:OCX) had its price target reduced by Lake Street Capital from $6.00 to $4.00 in a research report issued on Tuesday, The Fly reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Lake Street Capital’s price target points to a potential upside of 23.84% from the company’s previous close.
A number of other analysts also recently weighed in on OCX. Needham & Company LLC reissued a “buy” rating and issued a $4.00 price target on shares of OncoCyte in a report on Wednesday, June 17th. Zacks Investment Research downgraded shares of OncoCyte from a “hold” rating to a “sell” rating in a report on Tuesday, June 16th. Piper Sandler increased their price target on shares of OncoCyte from $5.40 to $7.50 and gave the company an “overweight” rating in a report on Thursday, June 25th. Finally, Chardan Capital cut shares of OncoCyte from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $7.75 to $2.00 in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. OncoCyte presently has an average rating of “Buy” and an average target price of $4.05.
NYSEAMERICAN OCX opened at $3.23 on Tuesday. OncoCyte has a 1 year low of $1.50 and a 1 year high of $3.51.
OncoCyte (NYSEAMERICAN:OCX) last issued its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). The business had revenue of $0.02 million for the quarter.
In other OncoCyte news, major shareholder Broadwood Partners, L.P. acquired 1,050,000 shares of the company’s stock in a transaction dated Friday, April 24th. The stock was bought at an average price of $2.24 per share, for a total transaction of $2,352,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Several institutional investors have recently made changes to their positions in the stock. Phoenix Holdings Ltd. acquired a new stake in shares of OncoCyte during the 1st quarter worth about $628,000. Squarepoint Ops LLC acquired a new stake in shares of OncoCyte during the 1st quarter worth about $26,000. Two Sigma Investments LP acquired a new stake in OncoCyte in the 1st quarter valued at about $32,000. Geode Capital Management LLC increased its position in OncoCyte by 4.7% in the 1st quarter. Geode Capital Management LLC now owns 327,358 shares of the biotechnology company’s stock valued at $802,000 after acquiring an additional 14,593 shares in the last quarter. Finally, ETF Managers Group LLC increased its position in OncoCyte by 9.8% in the 1st quarter. ETF Managers Group LLC now owns 147,305 shares of the biotechnology company’s stock valued at $349,000 after acquiring an additional 13,092 shares in the last quarter.
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.
Recommended Story: Quiet Period Expirations
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.